| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $40,381,259 | 46 | 100 |
| Ticho Barry | CHIEF MEDICAL OFFICER | 0 | $0 | 16 | $1.25M | $-1.25M |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | 0 | $0 | 13 | $1.54M | $-1.54M |
| Krainer Adrian R. | director | 0 | $0 | 3 | $2.58M | $-2.58M |
| Kaye Edward M. MD | director | 0 | $0 | 13 | $4.41M | $-4.41M |
| Skorpios Trust | 10 percent owner | 0 | $0 | 1 | $30.6M | $-30.6M |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $40.38M worth of Stoke Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $28.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.
| 2026-03-02 | Sale | Krainer Adrian R. | director | 7,229 0.0138% | $39.66 | $286,715 | -13.22% | |
| 2025-12-08 | Sale | Kaye Edward M. MD | director | 13,430 0.023% | $32.27 | $433,385 | -2.79% | |
| 2025-12-08 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 3,978 0.0068% | $32.28 | $128,411 | -2.79% | |
| 2025-12-05 | Sale | Kaye Edward M. MD | director | 8,548 0.0152% | $31.32 | $267,761 | +4.21% | |
| 2025-12-05 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 3,662 0.0065% | $31.34 | $114,762 | +4.21% | |
| 2025-12-05 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 8,785 0.0156% | $31.29 | $274,898 | +4.21% | |
| 2025-12-04 | Sale | Kaye Edward M. MD | director | 6,453 0.0112% | $30.87 | $199,197 | +3.32% | |
| 2025-12-04 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 1,018 0.0018% | $30.87 | $31,425 | +3.32% | |
| 2025-12-04 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 1,696 0.003% | $30.87 | $52,353 | +3.32% | |
| 2025-12-03 | Sale | Kaye Edward M. MD | director | 1,070 0.0019% | $30.65 | $32,793 | +3.33% | |
| 2025-12-03 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 2,292 0.004% | $30.65 | $70,245 | +3.33% | |
| 2025-12-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 2,014 0.0035% | $30.65 | $61,725 | +3.33% | |
| 2025-12-02 | Sale | Kaye Edward M. MD | director | 1,066 0.0019% | $29.78 | $31,748 | +7.26% | |
| 2025-12-02 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 2,284 0.004% | $29.78 | $68,023 | +7.26% | |
| 2025-12-02 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 2,006 0.0035% | $29.78 | $59,743 | +7.26% | |
| 2025-11-24 | Sale | Krainer Adrian R. | director | 40,472 0.0718% | $29.72 | $1.2M | +5.21% | |
| 2025-11-14 | Sale | Krainer Adrian R. | director | 40,472 0.0733% | $26.98 | $1.09M | +19.73% | |
| 2025-11-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 5,931 0.0093% | $25.72 | $152,566 | +19.67% | |
| 2025-10-08 | Sale | Kaye Edward M. MD | director | 25,000 0.0449% | $30.00 | $750,000 | +3.11% | |
| 2025-10-03 | Sale | Kaye Edward M. MD | director | 42,461 0.0827% | $25.09 | $1.07M | +22.89% |
| Skorpios Trust | 10 percent owner | 3906181 6.8389% | $134.45M | 0 | 4 | |
| Krainer Adrian R. | director | 316545 0.5542% | $10.9M | 0 | 3 | |
| Kaye Edward M. MD | director | 49124 0.086% | $1.69M | 0 | 21 | |
| Ticho Barry | CHIEF MEDICAL OFFICER | 19798 0.0347% | $681,447.16 | 0 | 45 | |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | 11831 0.0207% | $407,223.02 | 0 | 19 | |
| Harrison Seth Loring | 17161713 30.0465% | $590.71M | 2 | 0 | <0.0001% | |
| Apple Tree Partners IV, L.P. | 10 percent owner | 17161713 30.0465% | $590.71M | 2 | 0 | <0.0001% |
| RTW INVESTMENTS, LP | 10 percent owner | 3544248 6.2052% | $121.99M | 6 | 1 | <0.0001% |
| Liau Gene | EVP Research & Preclinical Dev | 21351 0.0374% | $734,901.42 | 0 | 7 | |
| Tulipano Stephen J | CFO | 20746 0.0363% | $714,077.32 | 0 | 6 | |
| LEVIN ARTHUR A | director | 0 0% | $0 | 0 | 1 | |
| TZIANABOS ARTHUR | director | 0 0% | $0 | 0 | 2 | |
| Nash Huw M. | Chief Business Officer | 0 0% | $0 | 0 | 30 | |
| Walker Robin A. | Chief Legal Officer, CCO & Sec | 0 0% | $0 | 0 | 1 |
$21,345,882 | 83 | 94.45% | $1.8B | |
$54,590,806 | 65 | 21.84% | $2.4B | |
$1,376,668 | 53 | 18.46% | $1.77B | |
$571,486,799 | 46 | 4.46% | $2.28B | |
$1,603,489 | 30 | 98.90% | $1.96B | |
$62,927,079 | 29 | 14.02% | $2.05B | |
$82,281,805 | 29 | -1.52% | $1.89B | |
$8,195,601 | 23 | -12.08% | $2.07B | |
$18,854,717 | 21 | 22.51% | $1.98B | |
$73,814,940 | 15 | -4.77% | $2.47B | |
$144,557,026 | 13 | 0.49% | $1.91B | |
$2,859,892 | 10 | 29.21% | $1.88B | |
Stoke Therapeutics, Inc. (STOK) | $94,976,497 | 10 | -10.72% | $1.97B |
$93,268,646 | 8 | -37.22% | $1.88B | |
$4,623,072 | 7 | 11.07% | $2.11B | |
$7,605,533 | 5 | 17.10% | $1.91B | |
$3,200,000 | 5 | -11.36% | $1.76B | |
$666,380 | 5 | -16.60% | $2.13B | |
$24,000,085 | 4 | 33.26% | $2.31B |
| Increased Positions | 100 | +60.24% | 8M | +12.06% |
| Decreased Positions | 71 | -42.77% | 8M | -11.24% |
| New Positions | 45 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 195 | +17.47% | 69M | +0.82% |
| Fmr Llc | $212,130.00 | 12.04% | 6.87M | -547,925 | -7.39% | 2025-09-30 |
| Blackrock, Inc. | $185,012.00 | 10.5% | 5.99M | +62,874 | +1.06% | 2025-09-30 |
| Lynx1 Capital Management Lp | $167,004.00 | 9.48% | 5.4M | 0 | 0% | 2025-09-30 |
| Rtw Investments, Lp | $158,317.00 | 8.99% | 5.12M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $143,186.00 | 8.13% | 4.63M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $129,024.00 | 7.33% | 4.18M | -200,389 | -4.58% | 2025-09-30 |
| Morgan Stanley | $109,295.00 | 6.21% | 3.54M | -36,926 | -1.03% | 2025-09-30 |
| Toronto Dominion Bank | $98,054.00 | 5.57% | 3.17M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $97,764.00 | 5.55% | 3.16M | +217,616 | +7.39% | 2025-09-30 |
| Skorpios Trust | $69,716.00 | 3.96% | 2.26M | -1M | -30.71% | 2025-09-30 |